Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $818.00 by Analysts at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective trimmed by Truist Financial from $820.00 to $818.00 in a research note published on Monday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on REGN. Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Canaccord Genuity Group increased their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Finally, Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and upped their price target for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $799.74.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $755.02 on Monday. The stock has a market cap of $79.35 billion, a PE ratio of 18.17, a price-to-earnings-growth ratio of 1.92 and a beta of 0.40. The stock has a 50-day moving average of $758.27 and a 200-day moving average of $652.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $12.07 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of REGN. Osaic Holdings Inc. grew its position in shares of Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in shares of Regeneron Pharmaceuticals by 153.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after acquiring an additional 73,176 shares during the period. PGGM Investments lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% in the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after acquiring an additional 8,187 shares during the period. Bellecapital International Ltd. boosted its holdings in Regeneron Pharmaceuticals by 32.7% in the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 6,283 shares during the last quarter. Finally, Rakuten Investment Management Inc. bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $33,121,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan sharply raised its price target to $950 and moved to “overweight,” signaling a sizable upside thesis tied to Regeneron’s recent results and trajectory. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed “outperform” and lifted its target to $865, showing dealer conviction that Q4 results justify higher analyst estimates. Benzinga
• Positive Sentiment: Cantor Fitzgerald and Wells Fargo raised targets (to $800), with Cantor keeping an “overweight” view — reinforcing industrywide upgrades following the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted EYLEA HD Phase 3 presentations at Angiogenesis 2026 (final 64‑week QUASAR and full ELARA results), which support the drug’s clinical profile and could underpin retinal franchise growth. EYLEA HD Presentations
• Positive Sentiment: Investors are digesting the company’s upbeat Q4 report (EPS and revenue beats) and accompanying earnings call commentary that boosted near‑term visibility. Q4 Earnings Transcript
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a modest adjustment that suggests limited conviction for sizable near‑term upside. TickerReport
• Neutral Sentiment: Truist trimmed its target slightly (to $818) but maintained a “buy,” reflecting minor calibration rather than a change in long‑term view. TickerReport
• Neutral Sentiment: Market commentary and pieces on Regeneron’s pipeline vs. valuation highlight a valuation gap and focus investors on execution of key pipeline catalysts over the next 12–24 months. Yahoo Finance

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.